09
Sep
Glenmark Pharma shares rose 3% to an intraday high of ₹2,112.60 on Tuesday, September 9. The company announced that its wholly-owned subsidiary has received an upfront payment of $700 million from AbbVie. "This payment is in accordance with agreed contractual terms and is being made under an exclusive global licensing agreement for IGI's key investigational asset, ISB 2001, in the North America, Europe, Japan and Greater China markets," Glenmark said in a regulatory filing. On July 10, 2025, New York-based Ichnos will acquire Glenmark Innovations, Inc. IGI Therapeutics SA, a wholly-owned subsidiary of IGI, and AbbVie have announced an exclusive…
